Investors
Solvotrin Therapeutics Limited is a privately held pharmaceutical company with a portfolio of innovative products for the treatment of cardiovascular disease and cancer.
Solvotrin Therapeutics’ intellectual property protects a family of bioactivated medicines with significant clinical advantages over currently available drugs.
Solvotrin Therapeutics will commence fundraising in Q1, 2012 for further development of its portfolio. For more information, please contact Pat O’Flynn.
Solvotrin Tel. +353 21 4205340